Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - GO MEDICAL INDUSTRIES PTY LTD, ROYAL HOBART HOSPITAL / PHARMACY DEPARTMENT, INTEGRIA HEALTHCARE AUSTRALIA PTY LTD, HOSPIRA PTY LIMITED, SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE LTD, MARLEEN HERBS OF TASMANIA, SYMBION CONTRACT LOGISTICS and STEMTECH PTY LTD

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia's Parliament, aims to ensure that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. The Act establishes a comprehensive regulatory framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. The problem or gap this legislation addresses is the need to maintain and improve public health by regulating the manufacture, supply, and advertising of therapeutic goods, ensuring that they are safe, of good quality, and effective. This is achieved by requiring manufacturers to hold appropriate licences and by setting out the conditions and standards that must be met. Under the authority of the Therapeutic Goods Act 1989, the Therapeutic Goods Administration, through its delegate Dr Harry Rothenfluh, publishes details concerning the grant of licences to specific entities for the manufacture of therapeutic goods. This publication, dated 20 February 2015, lists the companies that have been granted licences to manufacture therapeutic goods, thereby ensuring that these companies meet the necessary regulatory requirements and standards set forth in the Act. The policy objective is to safeguard public health by ensuring that only licensed manufacturers can produce therapeutic goods in Australia, thereby maintaining the integrity and safety of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, applies to entities involved in the manufacture, supply, import, export, and advertising of therapeutic goods within Australia. The Act sets out the legislative framework for ensuring that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods under Section 38 of the Act identifies entities that have been approved to produce such goods, ensuring that they meet the regulatory standards required for distribution within the Australian market. This Act applies across the Commonwealth of Australia, encompassing all states and territories, thereby establishing a uniform standard for therapeutic goods across the nation. The scope of the Act is inclusive of a wide range of therapeutic goods, from prescription and over-the-counter medicines to medical devices and blood products. The Act’s application extends to both domestic and foreign entities, provided they engage in the manufacture of therapeutic goods within Australia or supply such goods into the Australian market. The Act includes mechanisms for exemptions and exclusions, such as for research and development activities under certain conditions, and thresholds that determine the level of regulatory scrutiny required. Subordinate instruments and regulations may further refine the application of the Act, providing detailed operational guidelines and additional criteria for compliance.

Key Provisions

The key provisions of the Therapeutic Goods Act 1989 relevant to this publication include Section 38, which outlines the grant of a Licence to Manufacture Therapeutic Goods. This section allows the Secretary to grant licences to entities that meet the necessary criteria for manufacturing therapeutic goods. The licences granted, as mentioned in the publication, are detailed under Section 38, specifying the licence number, the company name, and its address. These licences include, for example, MI-2013-LI-07109-1 for Go Medical Industries Pty Ltd and MI-2013-LI-06998-1 for Royal Hobart Hospital / Pharmacy Department. Each licence represents the approval for the respective company to manufacture therapeutic goods within the scope of their operations. The obligations imposed on the licence holders under the Therapeutic Goods Act 1989 are primarily centred around maintaining the quality and safety standards of the therapeutic goods they manufacture. The licence holders must comply with all applicable regulations and standards set forth by the Therapeutic Goods Administration (TGA). This includes adhering to good manufacturing practices (GMP), ensuring that the therapeutic goods produced meet the required quality and safety standards, and maintaining appropriate records and documentation related to the manufacturing process. Failure to comply with these obligations can result in the suspension or revocation of the licence. In terms of offences, penalties, or consequences for breach, the Therapeutic Goods Act 1989 provides a framework for enforcement actions against entities that do not comply with the Act's provisions. For instance, if a licence holder fails to maintain the required standards, the TGA can take enforcement actions such as issuing infringement notices, imposing fines, or even prosecuting the company for serious breaches. The maximum penalties can include substantial fines and potential imprisonment for individuals found guilty of serious offences. Additionally, the TGA can suspend or revoke the licence, effectively prohibiting the entity from manufacturing therapeutic goods until compliance is achieved.